| |
Immune checkpoint inhibitors offer significant survival benefit, yet many patients do not respond to these treatments. Dosing optimization offers hope. Learn how to maximize therapeutic efficacy and minimize toxicity of ICIs in our guide. .png)
|
|
Today’s Big NewsSep 30, 2024 |
|
These awards honor CROs that excel in innovation, quality, and leadership, highlighting their crucial role in advancing life sciences and improving patient outcomes. Enter now! 
|
|
| By Nick Paul Taylor Genentech is paying $850 million upfront for Regor Pharmaceuticals’ portfolio of CDK inhibitors, taking ownership of a breast cancer candidate that has shown signs of single-agent efficacy in patients failed by existing options. Roche, Genentech’s parent company, also disclosed the acquisition of AntlerA. |
|
|
|
By Nick Paul Taylor Bristol Myers Squibb is paying Prime Medicine $110 million upfront to develop reagents for ex vivo T-cell therapies. Prime, which could receive a whopping $3.5 billion in milestones, disclosed the deal alongside details of a pipeline prioritization intended to extend its cash runway into the first half of 2026. |
By Zoey Becker The voluntary hold comes after Kezar restructured last year to in a bid to support its lupus and hepatitis candidate zetomipzomib. |
By James Waldron Rivus Pharmaceuticals has unveiled the data behind its phase 2 obesity win in heart failure patients, showing that the candidate can indeed help patients reduce weight while they retain muscle. |
|
This white paper delves into key challenges in ADC development and explores new drug product capabilities in cytotoxic drug development and manufacturing, accelerating timelines to IND filing and beyond. 
|
|
By James Waldron Having banked $60 million from Eli Lilly in the spring, Aktis Oncology has now closed an upsized $175 million series B that saw the U.S. Big Pharma rejoin a range of big-name investors in the radiopharma biotech. |
By James Waldron Cereno Scientific’s hypertension drug was shown to improve the risk score of 43% of patients in a phase 2 study. |
By Darren Incorvaia BridgeBio Pharma has been on the road to redemption ever since its treatment for a rare and fatal heart condition, acoramidis, flopped in an early readout of phase 3 data. Three years since tripping over that hurdle, the Bay Area company is now revealing that at the end of that trial, acoramidis had reduced combined all-cause mortality and recurrent cardiovascular-related hospitalizations compared to placebo in patients with transthyretin amyloid cardiomyopathy. |
By Gabrielle Masson,Darren Incorvaia,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Darren Incorvaia Tampa’s Moffitt Cancer Center is forging an international partnership with Japan’s largest CRO, CMIC, to improve the ability of both organizations to run global cancer trials. |
By Angus Liu After putting on a strong performance in preventing disease progression, Johnson & Johnson and Legend Biotech’s Carvykti has once again demonstrated a major benefit—this time in prolonging patients’ lives. |
By Conor Hale A prostate cancer trial compared two types of radiation treatments head-to-head, and found both helped control tumors with no differences in quality of life. |
Fierce podcasts Don’t miss an episode |
| In this week's "The Top Line," Fierce journalists discuss key issues from promising but debated lung cancer data at recent conferences. |
|
|---|
|
|
|
Optimize Bioprocessing with Scalable Solutions – Achieve Higher Yields, Greater Purity, and Faster Time-to-market. 
|
|
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper Unique Solutions for Drug Discovery and Development Sponsored by: Cell Signaling Technology |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
Whitepaper We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| Submissions Deadline Sept 12th |
|
|
| |
|
